Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI)
August 25, 2014 16:30 ET
|
Kite Pharma, Inc.
Phase 1-2a Clinical Trial Highlights:
12 of 13 Total Evaluable Patients with Advanced B Cell Malignancies Had Complete Remissions (8 Patients) or Partial Remissions (4 Patients) Resulting in a...
Kite Pharma Reports Second Quarter 2014 Results
August 14, 2014 17:40 ET
|
Kite Pharma, Inc.
Successfully Completed Initial Public Offering, Raised Net Proceeds of $134.1 Million
Kite Advancing Clinical Development Pipeline of Its Proprietary eACT™-Based Product Candidates
SANTA...
Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
June 23, 2014 07:30 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Announces Pricing of Initial Public Offering
June 20, 2014 06:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., June 20, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...